Voclosporin is a next generation calcineurin inhibitor that Isotechnika has licensed to Lux for ophthalmic indications.
Isotechnika Inc. announced on Thursday that their partner, Lux Biosciences, Inc., reported the results from the three Phase 3 LUMINATE trials investigating voclosporin oral capsule (LUVENIQ(TM) or LX211) for the treatment of uveitis.
The data show a positive effect on ocular inflammation and a safety profile consistent with the expected use in uveitis.
Following full analysis of the data, the results of the LUMINATE clinical trials will be submitted for publication and presented at upcoming conferences. In parallel, Lux Biosciences will be preparing submissions for approval.
LUMINATE Program enrolled 558 patients in 7 countries including United States, Canada, United Kingdom, France, Germany, Austria and India.
Voclosporin is designed for use as an oral immune-modulatory agent to treat the forms of non-infectious uveitis that require systemic treatment, including posterior, intermediate and panuveitis, allowing for tapering of systemic corticosteroids to 5 mg or less per day.
Source:RTTNews
Filed under Eye Care Products, Eye Care Program, Eye Treatment, blindness. | Tags: France, LUVENIQ(TM), ophthalmic indications, uveitis, voclosporin oral capsule | Comment Below
Related?
Can-Fite Begins Phase II Trials for Treatment of Symptoms of Keratitis Sicca (Dry-Eye Syndrome)January 31st, 2007 Can-Fite BioPharma Ltd. (TASE:CFBI) has begun Phase II clinical trials for its CF101 drug for the treatment of symptoms of keratitis sicca (dry-eye syndrome).
Novagali eye Treatment for Vernal Keratoconjunctivitis (VKC) Successful in Phase III TrialApril 10th, 2007 Israeli-French drug development company Novagali SA, which was founded on the basis of research conducted by Prof. Simon Benita of the Hebrew University of Jerusalem, has successfully completed European Medicines Agency (EMEA) Phase III clinical trials of its eye treatment for Vernal Keratoconjunctivitis (VKC)..
Comparative study between Durezo and Pred Forte proves successful in pivotal anterior uveitis trial October 15th, 2008 Sirion Therapeutics, Inc., has announced the results of the trial that compared Durezo 0.05% dosed four times daily (QID) to Pred Forte(R) (prednisolone acetate ophthalmic suspension) 1%, dosed eight times daily. The primary endpoint was the difference from baseline in anterior chamber (AC) cell grades between the Durezol and Pred Forte groups.
'Diabetes Macular Edema' drug 'Iluvien' is on its final trial phaseApril 8th, 2009 Alimera Sciences, today reported that an independent Data Safety Monitoring Board (DSMB) has recommended the continuation of two pivotal Phase 3 clinical trials for the use of Iluvien(TM) in the treatment of diabetic macular edema (DME). Alimera's Iluvien is an intravitreal insert being developed for the treatment of DME. Each Iluvien insert is designed to provide a sustained therapeutic effect, up to 36 months for the low dose and up to 24 months for the high dose.
Phase-II Clinical Trial of Drug Evizon for Wet Age-Related Macular DegenerationJune 28th, 2006 Biopharmaceutical company Genaera Corporation has commenced a multi-center phase II clinical trial to explore the efficacy and safety of higher doses of its investigational drug Evizon for the treatment of the eye disease, wet age-related macular degeneration. The study is designed to evaluate up to 140 patients with wet age-related macular degeneration (AMD) treated with Evizon at four dose levels of 40mg, 80mg, 120mg and 160mg over a 20 week period.
Ocular inflammation enhanced 2.2 fold by smokingMay 18th, 2009 In a study conducted by led author Phoebe Lin, MD, PhD, and colleagues revels that smoking resulted in almost 2.2 fold greater risk of having ocular inflammation or Uveitis. Uveitis means inflammation of the uvea, or the middle layer of the eye.
Clinical trial on Corticosteroid shows visible reduction in Posterior UveitisOctober 15th, 2008 Latest news reveals about the success of corticosteroid, Fluocinolone acetonide (FA) for the treatment of posterior uveitis. This was revealed by undergoing a long term clinical trial of more than 3 years.
Dry Age Related Macular Degenetation (AMD) drug shows positive result in phase 2 trialMarch 28th, 2009 NT-501, the lead product candidate of Neurotech Pharmaceutisals, inc., have successfully slowed down the loss of vision in a Phase 2 clinical trial, in patients suffering from macular degeneration along with geographic atrophy(GA). GA is a condition that destroys sharp central vision and causes serious vision loss to one or both eyes.
